Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

The 20th Anniversary event will bring back popular topics like immunomodulation, protein degraders, and RNA, plus transcription factors, small molecules for cancer targets, and kinases.

Catherine Stace (Executive VP, Business Development) will be there.